Kite Pharma is flying high with the addition of a new member to its senior leadership team. | Kite Pharma is flying high with ...

Gilead signed a massive deal with Galapagos. After a restructuring, the pharma is still hunting for the potential it saw at ...

The FDA has approved Kite Pharma's Tecartus as a treatment for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia (ALL), making CAR-T therapy an option for an ...

Gilead Sciences’ Kite Pharma unit is closing on approval of its second European approval for a CAR-T for cancer, after the CHMP backed its KTE-X19 therapy for mantle cell lymphoma.

A California federal district court denied Gilead Sciences, Inc. and Kite Pharma, Inc.’s motion to dismiss unpaid overtime claims under the Fair Labor Standards Act by two cell therapy specialists ...

In a presentation at the recent American Society of Hematology meeting in San Diego, Kite Pharma Inc. reported preclinical data for KITE-753, an autologous rapid manufactured anti-CD19/CD20 CAR T-cell ...

Through its partnership in 2017 with California-based Kite Pharma, Fosun Pharma has been co-developing the CAR-T therapy in China. Its biopharmaceutical platform, Henlius is developing biosimilars ...